Antibody–Drug Conjugate plus Immunotherapy for Advanced Triple-Negative Breast Cancer

Patients with metastatic triple-negative breast cancer need additional treatment options despite improvements in outcome for some treated with chemotherapy and immunotherapy combinations or with antibody–drug conjugates such as sacituzumab govitecan (SG).

Now, investigators have reported results of the industry-sponsored, phase 3, ASCENT-04/KEYNOTE-D19 study. The 443 enrolled patients (median age, 54 years) had previously untreated, locally advanced or metastatic, programmed death ligand 1 (PD-L1)–positive, triple-negative breast cancer (TNBC) and were randomized to receive pembrolizumab plus either chemotherapy (chemoP) or SG (SGP). The primary end point of the study was progression-free survival (PFS).